| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
Department of Cancer Prevention, Epidemiology and Biostatistics, Roswell Park Cancer Institute, Buffalo, New York 14263 [K. B. M., C. M., N. N., R. J. M., H. S.], and Sisters Specialty Center for Women, Buffalo, New York 14214 [M. S. P.]
Analgesics have been shown to reduce risk for colorectal cancer. Results from three recent reports (D. W. Cramer et al., Lancet, 351: 104–107, 1998; C. Rodriguez et. al., Lancet, 352: 1354–1355, 1998; L. Rosenberg et al., Cancer Epidemiol. Biomark. Prev., 9: 933–937, 2000) suggest that these drugs might be associated with decreased risk for ovarian cancer. In this hospital-based case-control study, we compared 547 patients with ovarian cancer to 1094 age-matched patients with nonneoplastic conditions. All of the participants received treatment at the Roswell Park Cancer Institute between 1982 and 1998 and completed a comprehensive epidemiological questionnaire that included information on demographics, life-style factors, and reproductive characteristics as well as frequency and duration of aspirin and acetaminophen use. Women who reported that they had used one or more of these agents at least once a week for at least 6 months were classified as analgesic users. Logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Aspirin users were not at reduced risk of ovarian cancer compared with nonusers (adjusted OR, 1.00; CI, 0.73–1.39). There was also no evidence of a decrease in risk as a function of greater frequency of use or prolonged duration of use. Regular acetaminophen use was associated with a reduced risk (adjusted OR, 0.56; 95% CI, 0.34–0.86), and risk reductions were observed for women with the greatest frequency of use (adjusted OR, 0.32; 95% CI, 0.09–1.08) and longest duration of use (adjusted OR, 0.51; 95% CI, 0.27–0.97). These data suggest that regular use of acetaminophen, but not aspirin, may be associated with lower risk of ovarian cancer.
This article has been cited by other articles:
|
|
 |
|
  C. G. Hannibal, M. A. Rossing, K. G. Wicklund, and K. L. Cushing-Haugen Analgesic Drug Use and Risk of Epithelial Ovarian Cancer Am. J. Epidemiol., June 15, 2008; 167(12): 1430 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Moysich, J. A. Baker, R. J. Menezes, V. Jayaprakash, K. J. Rodabaugh, K. Odunsi, G. P. Beehler, S. E. McCann, and J. A. Villella Usual Adult Body Mass Index Is Not Predictive of Ovarian Cancer Survival Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 626 - 628. [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Beehler, M. Sekhon, J. A. Baker, B. E. Teter, S. E. McCann, K. J. Rodabaugh, and K. B. Moysich Risk of Ovarian Cancer Associated with BMI Varies by Menopausal Status J. Nutr., November 1, 2006; 136(11): 2881 - 2886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Baker, G. P. Beehler, A. C. Sawant, V. Jayaprakash, S. E. McCann, and K. B. Moysich Consumption of Coffee, but Not Black Tea, Is Associated with Decreased Risk of Premenopausal Breast Cancer J. Nutr., January 1, 2006; 136(1): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Moysich, J. A. Baker, K. J. Rodabaugh, and J. A. Villella Regular Analgesic Use and Risk of Endometrial Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2923 - 2928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer Cancer Res., May 1, 2005; 65(9): 3735 - 3744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore Cyclooxygenase-2 and its role in ovulation: a 2004 account Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Sivak-Sears, J. A. Schwartzbaum, R. Miike, M. Moghadassi, and M. Wrensch Case-Control Study of Use of Nonsteroidal Antiinflammatory Drugs and Glioblastoma Multiforme Am. J. Epidemiol., June 15, 2004; 159(12): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Chang, T. Zheng, E. G. Weir, M. Borowitz, R. B. Mann, D. Spiegelman, and N. E. Mueller Aspirin and the Risk of Hodgkin's Lymphoma in a Population-Based Case-Control Study J Natl Cancer Inst, February 18, 2004; 96(4): 305 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Terry, L. Titus-Ernstoff, E. O. Garner, A. F. Vitonis, and D. W. Cramer Interaction between CYP1A1 Polymorphic Variants and Dietary Exposures Influencing Ovarian Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Gupta, L. V. Tejada, B. J. Tong, S. K. Das, J. D. Morrow, S. K. Dey, and R. N. DuBois Cyclooxygenase-1 is Overexpressed and Promotes Angiogenic Growth Factor Production in Ovarian Cancer Cancer Res., March 1, 2003; 63(5): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Barnes, W. E. Grizzle, C. J. Grubbs, and E. E. Partridge Paradigms for Primary Prevention of Ovarian Carcinoma CA Cancer J Clin, July 1, 2002; 52(4): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Mills Mechanisms Underlying Chemoprevention of Ovarian Cancer Clin. Cancer Res., January 1, 2002; 8(1): 7 - 10. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
